Open AccessSecond primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients
Author(s) -
Mora Barbara,
Rumi Elisa,
Guglielmelli Paola,
Barraco Daniela,
Maffioli Margherita,
Rambaldi Alessandro,
Caramella Marianna,
Komrokji Rami,
Gotlib Jason,
Kiladjian Jean Jacques,
Cervantes Francisco,
Devos Timothy,
Palandri Francesca,
Stefano Valerio,
Ruggeri Marco,
Silver Richard T.,
Benevolo Giulia,
Albano Francesco,
Cavalloni Chiara,
Pietra Daniela,
Barbui Tiziano,
Rotunno Giada,
Cazzola Mario,
Vannucchi Alessandro Maria,
Giorgino Toni,
Passamonti Francesco
Publication year - 2019
Publication title -
cancer medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 53
ISSN - 2045-7634
DOI - 10.1002/cam4.2107
Subject(s) - myelofibrosis , incidence (geometry) , medicine , polycythemia vera , cohort , population , melanoma , essential thrombocythemia , dermatology , oncology , cancer research , bone marrow , physics , environmental health , optics
Patients with myeloproliferative neoplasms (MPN) are known to have higher incidence of nonhematological second primary malignancies (SPM) compared to general population. In the MYSEC study on 781 secondary myelofibrosis (SMF) patients, the incidence of SPM after SMF diagnosis resulted 0.98/100 patient‐years. When including non‐melanoma skin cancers (NMSC), the incidence arose to 1.56/100 patient‐years. In SMF, JAK inhibitor treatment was associated only with NMSC occurrence. Then, we merged the MYSEC cohort with a large dataset of PV and ET not evolving into SMF. In this subanalysis, we did not find any correlation between SPM and SMF occurrence. These findings highlight the need of studies aimed at identifying MPN patients at higher risk of SPM.